CA
MTNB icon

Cliff Asness’s Matinas BioPharma MTNB Stock Holding History

Cliff Asness’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-289
Closed -$17K – 2259
2017
Q4 		$17K Hold
289
– – ﹤0.01% 2214
2017
Q3 		$19K Buy
+289
New +$19.3K ﹤0.01% 2233

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AWMG
Alliance Wealth Management Group Flemington, New Jersey $514M AUM 16.05% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Cliff Asness's MTNB Position: Q1 2018 in Review

Cliff Asness sold out of Matinas BioPharma (MTNB) in Q1 2018, closing a stake of 289 shares — an estimated $17K sold.

Cliff Asness first reported a position in MTNB in Q3 2017 and held it in 2 quarters. The position peaked at $19K in Q3 2017. 45 funds tracked by Wall St. Rank hold MTNB as of Q1 2018.

  • Cliff Asness reported no remaining Matinas BioPharma position as of Q1 2018 after selling out during the quarter.
  • Cliff Asness sold 289 Matinas BioPharma shares in Q1 2018, an estimated $17K.
  • Cliff Asness first reported a position in Matinas BioPharma in Q3 2017 and held it in 2 quarters.
  • Cliff Asness's Matinas BioPharma position peaked at $19K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2018.

Based on AQR Capital Management's 13F filing for Q1 2018, filed 15 May 2018.